News

In September 2004 the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a

Novartis will continue to use the Xenogen software and patented methods of biophotonic imaging for use with Xenogen’s biophotonic imaging systems. The technology will be used for research

Vertex expects to recognize revenue of approximately $7 million of the $19.5 million in milestone payments in the fourth quarter of 2005, and the balance in 2006. In

The first is a follow-on study of TRX4 in subjects with type 1 diabetes. Previous phase I studies have shown TRX4 can preserve the function of insulin-producing beta

The study will look at the effects of ALN-RSV01 in healthy volunteers in two separate phase I trials. The first trial underway in Europe and is expected to

According to Stem Cell Therapeutics (SCT), analysis and reporting of the phase I trial is anticipated within the first quarter of 2006. The study is expected to characterize

Under the agreement, which is Xencor’s fifth for this technology in the last year, MedImmune will be able to use Xencor’s XmAb proprietary engineered Fc domains to enhance

The US biotech giant has agreed to pay Galapagos in excess of $30 million, should all clinical and commercial events currently programmed be achieved. The collaboration covers computational

The global phase III study has enrolled13,800 patients to help evaluate Angiomax (bivalirudin) as a replacement to the commonly used anticoagulant heparin in patients with acute coronary syndromes.